Fresenius Medical Care (FMS) Company Report

Fresenius Medical Care (FME) successfully placed a bond with a volume of €500 million on November 17, 2025.
The bond matures in November 2030 and has a coupon of 3.250%, issued at a price of 99.619%, resulting in a yield of 3.334%.
The proceeds from this bond will be used for general corporate purposes, including the refinancing of existing financial liabilities.

Nov 17, 2025, 6:31 PM

6-K

Fresenius Medical Care Reports Strong Q3 2025 Results and Updates Full-Year Guidance

FMS

Earnings

Guidance Update

Share Buyback

Fresenius Medical Care (FMS) reported strong Q3 2025 organic revenue growth of 10% and an accelerated operating income growth of 28%, with the operating income margin expanding to 11.7%.
The company initiated a EUR 1 billion share buyback program, repurchasing 4.35 million shares for EUR 188 million by October 31.
FMS updated its full-year 2025 outlook, expecting EUR 220 million in savings from FME25 plus and EUR 180 million in contributions from phosphate binders, and reiterated its full operating income guidance range.
Strategic initiatives are progressing, including the early rollout of high volume HDF treatments in select U.S. clinics and an increased ownership stake in intoWell Health for value-based care.

Nov 4, 2025, 1:00 PM

Transcript

Fresenius Medical Care Reports Strong Q3 2025 Organic Revenue and Earnings Growth

FMS

Earnings

Revenue Acceleration/Inflection

Share Buyback

Fresenius Medical Care achieved strong organic revenue growth of 10% and accelerated operating income growth of 28% (at constant currency, excluding special items) in Q3 2025, leading to an operating income margin of 11.7%.
For Q3 2025, reported revenue increased by 3% to EUR 4,885 million, and basic earnings per share (excluding special items) rose by 37% to EUR 1.10.
The company's net leverage ratio improved to 2.6x in Q3 2025, and it commenced an initial share buyback program of EUR 1.0 billion, with EUR 151 million invested as of September 30, 2025.
Fresenius Medical Care confirmed its outlook for fiscal year 2025, expecting positive to low-single-digit percent revenue growth and high-teens to high-twenties percent operating income growth (excluding special items).

Nov 4, 2025, 12:00 PM

Press Release

Fresenius Medical Care AG Reports Q3 2025 Financial Results

FMS

Earnings

Management Change

Fresenius Medical Care AG reported Q3 2025 revenue of €4,885 million, an increase of 3% (or 8% at constant currency) compared to Q3 2024, with net income attributable to shareholders rising 29% to €275 million (or 34% at constant currency).
For the nine months ended September 30, 2025, total revenue grew 2% to €14,558 million (or 5% at constant currency), and basic earnings per share increased to €2.22 from €1.61 in the same period of 2024.
The Value-Based Care segment demonstrated strong performance, with Q3 2025 revenue increasing 34% (or 42% at constant currency) to €576 million, primarily due to organic growth from contract expansion and increased Member Months.
Joseph E. (Joe) Turk was appointed to the Management Board, effective January 1, 2026.

Nov 4, 2025, 11:02 AM

6-K

Fresenius Medical Care AG Reports Strong Q3 2025 Earnings and Confirms Full-Year Outlook

FMS

Earnings

Guidance Update

Share Buyback

Fresenius Medical Care AG reported 10% organic revenue growth and 28% operating income growth at constant currency for the third quarter of 2025, with the Group operating income margin (excluding special items) reaching 11.7%. Reported net income increased by 29%.
The company's net leverage ratio further improved to 2.6x in Q3 2025, and total net debt and lease liabilities were reduced to EUR 9,218 million.
As part of its FME Reignite strategy, Fresenius Medical Care AG launched the first tranche of its share buyback program, repurchasing 3.6 million shares for EUR 151 million as of September 30, 2025, and increased its ownership in Interwell Health.
The company confirmed its fiscal year 2025 outlook, expecting revenue growth at a positive low-single digit percent rate and operating income (excluding special items) growth at a high-teens to high-twenties percent rate, both at constant currency.

Nov 4, 2025, 11:00 AM

6-K

Fresenius Medical Care Increases Interwell Health Ownership and Appoints New CEO

FMS

New Projects/Investments

Management Change

Revenue Acceleration/Inflection

Fresenius Medical Care (FME) invested EUR 312 million to increase its ownership stake in Interwell Health (IWH), accelerating the timeline originally set for this transaction.
Tommy P. O’Connor has been appointed as the new CEO of Interwell Health and business segment leader of Value-Based Care, effective October 1, 2025, succeeding Robert Sepucha.
Interwell Health (IWH) generated EUR 1,035 million in revenue for the first six months of the year and experienced 23.5% revenue growth during this period.

Sep 19, 2025, 11:31 AM

6-K

Fresenius Medical Care Increases Interwell Health Ownership and Appoints New CEO

FMS

M&A

Management Change

New Projects/Investments

Fresenius Medical Care (FME) invested EUR 312 million to increase its ownership stake in Interwell Health (IWH), accelerating the timeline originally set during the August 2022 merger of Cricket Health, IWH, and Fresenius Health Partners.
Tommy P. O'Connor has been appointed CEO of Interwell Health and Operating Segment leader of Value-Based Care, effective October 1, 2025, succeeding Robert Sepucha.
Interwell Health generated EUR 1,035 million in revenue for the first six months of the year, experiencing 23.5% revenue growth during this period.

Sep 18, 2025, 7:30 PM

Press Release

Earnings Transcripts

Quarterly earnings call transcripts for Fresenius Medical Care.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What are Fresenius Medical Care's strategic priorities?How is Fresenius Medical Care positioned vs competitors?How did Fresenius Medical Care do last quarter?

Let Fintool AI Agent track Fresenius Medical Care's earnings for you

Get instant analysis when filings drop